ExpressionEdits, a biotechnology company optimising protein expression using AI and proprietary intronization technology, announced today a £10 million seed funding round co-led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.
Founded in 2021 by Dr. Kärt Tomberg, Professor Allan Bradley, and Dr. Liliana Antunes based on research from the University of Cambridge, the company’s proprietary intronization technology revolutionizes gene design by mimicking the natural genetic landscape. By strategically incorporating multiple short noncoding DNA sequences known as introns into artificial genes, ExpressionEdits has achieved significant enhancements in gene expression which leads to better protein production.
The funding will accelerate candidate selection for preclinical studies and develop a pipeline of protein-based therapeutics. The primary focus for the pipeline will be recombinant proteins that have historically faced production and manufacturing challenges based on current technology.
The company's AI-powered platform integrates millions of biological data points with machine learning algorithms, enabling automated optimization of gene design. This transformative technology empowers ExpressionEdits to predict and prioritise key properties of genes, unlocking the production of previously elusive therapeutic proteins.
ExpressionEdits’ Genetic Syntax Engine is a computational gene editing platform that uses advanced AI and deep biological insights to predict and redesign genes to unlock protein expression across therapeutic modalities. The technology aims to improve the effectiveness and precision of gene therapies, allowing for lower doses to achieve therapeutic levels, thus minimising toxicity, and expanding the genetic toolbox to further support the targeting of specific tissues, and increasing protein expression levels.
